Michael Barbella, Managing Editor04.10.24
Zynex Medical Inc. has received U.S. Food and Drug Administration (FDA) clearance for its next-generation M-Wave Neuromuscular Electrical Stimulation (NMES) device.
NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave, which has been used in NMES treatments throughout the United States since 1998. The E-Wave was the most powerful and versatile muscle stimulation device on the market for more than two decades and the M-Wave builds on that history of performance with a more intuitive design and additional functionality, according to the company.
"The M-Wave introduces the next evolution in NMES devices, allowing for more customizable treatments within clinical and home settings," Zynex Medical CEO Thomas Sandgaard said. "Our Product Management team has incorporated patient and physician feedback when designing the new M-Wave. The user-friendly interface and ease of use when designing a custom electrotherapy regimen will encourage an even broader adoption of Zynex's therapeutic products."
The M-Wave is designed to improve the way patients manage their neuromuscular conditions and allows patients to be treated quickly in a clinical or home setting.
Founded in 1996, Zynax develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. The company is based in Englewood, Colo.
NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave, which has been used in NMES treatments throughout the United States since 1998. The E-Wave was the most powerful and versatile muscle stimulation device on the market for more than two decades and the M-Wave builds on that history of performance with a more intuitive design and additional functionality, according to the company.
"The M-Wave introduces the next evolution in NMES devices, allowing for more customizable treatments within clinical and home settings," Zynex Medical CEO Thomas Sandgaard said. "Our Product Management team has incorporated patient and physician feedback when designing the new M-Wave. The user-friendly interface and ease of use when designing a custom electrotherapy regimen will encourage an even broader adoption of Zynex's therapeutic products."
The M-Wave is designed to improve the way patients manage their neuromuscular conditions and allows patients to be treated quickly in a clinical or home setting.
Founded in 1996, Zynax develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. The company is based in Englewood, Colo.